Treatment with trastuzumab as an add-on combined with chemotherapy has shown to be effective as a breast cancer treatment in patients which overexpress HER2, occurring in about 20% to 30% of all invasive breast cancer carcinoma (see, e.g., [21]). This evidence concerns the gene ERBB2 and breast carcinoma.